Review
Dermatology
A. Al-Hammadi, Z. Ruszczak, G. Magarinos, C-Y Chu, Y. El Dershaby, N. Tarcha
Summary: Continuous treatment with biologic agents is more effective than intermittent treatment for moderate-to-severe psoriasis, but intermittent treatment can be a viable option for patients who are unable or unwilling to maintain continuous therapy. Most patients are able to re-establish disease control following re-treatment, and adverse reactions during re-treatment are similar to those observed during continuous dosing.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
N. Loft, A. Egeberg, M. K. Rasmussen, L. E. Bryld, C. Nissen, T. N. Dam, K. K. Ajgeiy, L. Iversen, L. Skov
Summary: This study aims to identify and characterize patients with treatment refractory psoriasis and patients who are super-responders to biologic treatment. The results showed that treatment refractory patients had higher body weight, while super-responders had fewer comorbidities and higher socioeconomic status.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Infectious Diseases
Alemayehu Lelisa Duga, Francesco Salvo, Alexander Kay, Albert Figueras
Summary: This study analyzed the WHO database to investigate the magnitude and characteristics of adverse drug reactions (ADR) related to drug-resistant tuberculosis (DR-TB). The results showed that ADR has significant health consequences for individuals and can contribute to treatment non-adherence and drug resistance.
Article
Pharmacology & Pharmacy
Fabrizio Calapai, Ilaria Ammendolia, Luigi Cardia, Mariaconcetta Curro, Gioacchino Calapai, Emanuela Esposito, Carmen Mannucci
Summary: Risankizumab is a safe and effective treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis, according to post-marketing analysis of real-world data. The most frequently reported serious adverse reactions to risankizumab include infections, cancer, nervous system and cardiac disorders. Despite the limitations of the study, the safety profile of risankizumab is consistent with previous clinical trials and further research is needed to explore the occurrence of malignancies and their sex distribution as adverse reactions.
Article
Dermatology
Tetsuji Yanase, Noriko Tsuruta, Kazuki Yamaguchi, Chika Ohata, Bungo Ohyama, Eri Katayama, Kazunari Sugita, Maki Kuwashiro, Aki Hashimoto, Kentaro Yonekura, Yuko Higashi, Hiroyuki Murota, Yuta Koike, Yuki Matsuzaka, Satoko Kikuchi, Yutaka Hatano, Kanami Saito, Kenzo Takahashi, Takuya Miyagi, Sakae Kaneko, Masataka Ota, Kayo Harada, Shin Morizane, Kenta Ikeda, Masutaka Furue, Takeshi Nakahara, Fusako Okazaki, Natsuko Sasaki, Etsuko Okada, Yuichi Yoshida, Kotaro Ito, Shinichi Imafuku
Summary: This study investigated the real-world survival rate of systemic interventions for psoriasis treatment and found differences in the efficacy of biologics. The factors that negatively impact the survival rate of biologics include previous use of biologics, obesity, and psoriatic arthritis.
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Robert R. Mclean, Adam P. Sima, Silky Beaty, Eric A. Jones, Thomas Eckmann, Robert Low, Laura Mcclung, Rebecca L. Spitzer, Jeffrey Stark, April Armstrong
Summary: This study aimed to investigate the durability of near-complete skin clearance in patients with psoriasis and identify risk factors associated with the loss of near-complete skin clearance. The study found that about one-quarter of patients lost treatment response within 6 months, and half lost treatment response within 18 months. Prior use of biologic therapy and clinically meaningful skin symptoms at the start were associated with the loss of treatment response.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
P. Hampton, A. Halliday, M. Aassi, S. Subramanian, M. Jain, C. E. M. Griffiths
Summary: This study aimed to investigate the impact of prior exposure to systemic therapies on the efficacy and safety of secukinumab 300 mg for patients with moderate-to-severe psoriasis. The results showed that secukinumab was consistently more effective than placebo, etanercept, and ustekinumab after 12 weeks of treatment, regardless of patients' prior exposure to biologics or non-biologic systemic therapies.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Review
Pharmacology & Pharmacy
Vito Di Lernia, Laura Macca, Lucia Peterle, Ylenia Ingrasciotta, Gianluca Trifiro, Claudio Guarneri
Summary: The study found that biological therapies may provide short-term efficacy for moderate-to-severe psoriasis in children. The probability of achieving PASI 75 and PASI 90 was higher for IL-12/23 and IL-17 inhibitors, with a more favorable NNT. Therefore, these systemic drugs may be beneficial for treating plaque psoriasis in children and adolescents.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Dermatology
Richard G. Langley, Yves Poulin, Bhaskar Srivastava, Kimberly Parnell Lafferty, Steven Fakharzadeh, Wayne Langholff, Matthias Augustin
Summary: Biologic therapy was found to be associated with reduced mortality risk in patients with moderate to severe psoriasis, regardless of treatment duration. Methotrexate only reduced mortality risk after at least 1 year of exposure.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Pharmacology & Pharmacy
Marion Allouchery, Cecile Tomowiak, Thomas Lombard, Marie-Christine Perault-Pochat, Francesco Salvo
Summary: This study aimed to further characterize the safety profile of ibrutinib by identifying potential safety signals through a large-scale pharmacovigilance database. A total of 36 potential safety signals, mainly involving ischemic heart diseases and pericarditis, were identified in ibrutinib-treated patients. These findings may provide important implications for patient care and monitoring of ongoing clinical trials, but further confirmation through population-based studies is needed due to the limitations of this study.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Ahmed I. Mourad, Robert Gniadecki
Summary: Drug survival studies in psoriasis assessed the comparative effectiveness of biologics like ustekinumab, adalimumab, etanercept, infliximab, secukinumab, and ixekizumab in real-world settings. Results showed ustekinumab had the longest persistence, with adalimumab outperforming etanercept and infliximab at 5 years. The estimated pooled 2- and 5-year drug survival rates can serve as a useful tool for patient communication and clinical decision-making.
FRONTIERS IN MEDICINE
(2021)
Article
Dermatology
Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, Wolfgang Weger, Claudia Zikeli, Barbara Gruber, Paul Sator, Knut Prillinger, Alexander Mlynek, Martina Schuetz-Bergmayr, Leo Richter, Gudrun Ratzinger, Christoph Sassmann, Clemens Painsi, Nina Haering, Katharina Wippel-Slupetzky, Hans Skvara, Hannes Trattner, Martin Inzinger, Christina Bangert, Christina Ellersdorfer, Katharina Falkensteiner, Birgit Sadoghi, Alexandra Gruber-Wackernagel, Angelika Hofer, Franz Legat, Bernhard Lange-Asschenfeldt, Matthias Schmuth, Igor Vujic, Wolfram Hoetzenecker, Werner Saxinger, Robert Muellegger, Franz Quehenberger, Peter Wolf
Summary: This study analyzed the improvement in real-world psoriasis patients after the introduction of more effective treatments. The results showed that the continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes, although one out of three to five patients still does not achieve an entirely satisfactory treatment response.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Article
Dermatology
Carlos Pelayo Hernandez-Fernandez, Gregorio Carretero, Raquel Rivera, Carlos Ferrandiz, Esteban Dauden, Pablo De la Cueva, Isabel Belinchon, Francisco Javier Gomez-Garcia, Enrique Herrera-Acosta, Diana P. Ruiz-Genao, Marta Ferran, Merce Alsina, Ofelia Baniandres-Rodriguez, Jose Luis Sanchez-Carazo, Rafael Botella-Estrada, Antonio Sahuquillo-Torralba, Lourdes Rodriguez, Jaime Vilar-Alejo, Carmen Garcia-Donoso, Jose M. Carrascosa, Mar Llamas-Velasco, Enrique Herrera-Ceballos, Jose Luis Lopez-Estebaranz, Conrad Pujol-Marco, Miguel Angel Descalzo, Ignacio Garcia-Doval
Summary: This study found that women with psoriasis are more likely to be prescribed biologics than men, but there were no significant differences between sexes in terms of treatment effectiveness and risk of adverse events. Limitations of the study include residual confounding and the use of drug survival as a proxy for effectiveness.
ACTA DERMATO-VENEREOLOGICA
(2021)
Article
Pharmacology & Pharmacy
Christine P. Lin, Joseph F. Merola, Elizabeth B. Wallace
Summary: Psoriasis and psoriatic arthritis are chronic inflammatory diseases that have a negative impact on quality of life. Understanding the disease mechanisms is crucial for selecting treatment options.
CURRENT OPINION IN PHARMACOLOGY
(2022)
Article
Dermatology
J. -T. Maul, M. Augustin, C. Sorbe, C. Conrad, F. Anzengruber, U. Mrowietz, K. Reich, L. E. French, M. Radtke, P. Haeusermann, L. V. Maul, W. -H. Boehncke, D. Thaci, A. A. Navarini
Summary: The study found that women have better treatment outcomes with systemic antipsoriatic therapy compared to men, showing higher response rates in PASI and DLQI improvements.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Lisa A. Beck, Diamant Thaci, Mette Deleuran, Marjolein de Bruin-Weller, Zhen Chen, Faisal A. Khokhar, Meng Zhang, Zafer E. Ozturk, Brad Shumel
Summary: The study found that adults with moderate-to-severe AD treated with dupilumab for up to 3 years did not experience clinically significant changes in mean laboratory parameters, indicating that continuous long-term use of the treatment is supported without the need for laboratory monitoring.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Dermatology
D. Thaci, K. Eyerich, A. Pinter, M. Sebastian, K. Unnebrink, S. Rubant, D. A. Williams, P. Weisenseel
Summary: This study found that risankizumab was superior to FAEs in treating psoriasis, providing earlier and greater improvement in outcomes that persisted with continued treatment. Risankizumab also showed more favorable safety results with no new safety signals observed for either treatment arm.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Andrew Blauvelt, April W. Armstrong, Richard G. Langley, Kurt Gebauer, Diamant Thaci, Jerry Bagel, Lyn C. Guenther, Carle Paul, Bruce Randazzo, Susan Flavin, Ming-Chun Hsu, Yin You, Kristian Reich
Summary: In this study, guselkumab showed superior efficacy compared to secukinumab at week 48 in treating patients with moderate-to-severe plaque psoriasis, across various baseline characteristics. The largest differences in efficacy were observed in patients aged 65 and older, as well as in patients weighing over 100 kg.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Dermatology
James Krueger, Lluis Puig, Diamant Thaci
Summary: Generalized pustular psoriasis (GPP) is a rare and severe skin disorder without approved specific therapies. Current treatment options are based on limited evidence and recent advances have identified potential targets for targeted therapy based on improved understanding of the disease mechanisms and gene mutations associated with GPP.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Article
Rheumatology
Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaci, Thilo Klopsch, Anja Plenske, Lisa K. Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Loeschmann
Summary: This study investigated the proportion of German patients with rheumatoid arthritis who achieved remission or low disease activity after 12 and 24 weeks of etanercept treatment. It found that a considerable proportion of patients attained their treatment targets after 12 weeks, and the proportion further increased with longer treatment duration.
RHEUMATOLOGY AND THERAPY
(2022)
Article
Dermatology
Diamant Thaci, Ron Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B. Kimball
Summary: The clinical and health-related quality of life responses observed during the first 16 weeks of BE SURE were sustained over 2 years of treatment, regardless of bimekizumab maintenance dosing. Switching from adalimumab to bimekizumab also resulted in sustained improvements up to Week 104. Bimekizumab had a good safety profile with no new safety signals.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaci, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen
Summary: Baricitinib demonstrated a consistent safety profile in the long-term treatment of atopic dermatitis patients, with no new safety signals identified. The incidence rates of major adverse cardiovascular events, deep vein thromboses/pulmonary emboli, malignancies, and serious infections were within the ranges observed in the background population of patients with AD.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Dermatology
Matthias Augustin, Andrea Bauer, Konstantin Ertner, Ralph von Kiedrowski, Florian Schenck, Jutta Ramaker-Brunke, Sophie Moeller, Anja Fait, Mike Bastian, Diamant Thaci
Summary: The PROLEAD study examined the effectiveness and safety of dupilumab in real-world clinical practice for patients with moderate-to-severe atopic dermatitis (AD). The results showed that dupilumab was more effective and well tolerated in a real-world setting compared to phase 3 clinical trials.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Mark G. Lebwohl, Joseph F. Merola, Katelyn Rowland, Megan Miller, Ya-Wen Yang, Jenny Yu, Yin You, Daphne Chan, Diamant Thaci, Richard G. Langley
Summary: This study evaluated the safety of guselkumab in 2891 patients with psoriasis who were treated for up to 5 years. The findings showed that guselkumab demonstrated favorable safety, consistent with previous reports. The safety event rates in guselkumab-treated patients were similar to those observed in the placebo group and remained consistent throughout long-term treatment.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Letter
Dermatology
Andrew Blauvelt, Diamant Thaci, Kim A. Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Daphne Chan, Jenny Yu, Ya-Wen Yang, Mark G. Lebwohl, Alice B. Gottlieb, Jeffrey Crowley, Peter Foley
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
A. D. Burden, Y. Okubo, M. Zheng, D. Thaci, P. van de Kerkhof, N. Hu, M. Quaresma, C. Thoma, S. E. Choon
Summary: Effisayil 1 was a study investigating the use of spesolimab in patients with a flare-up of generalized pustular psoriasis (GPP). The study found that patients receiving spesolimab showed rapid clearance of pustules and skin symptoms within 1 week. The effectiveness and safety of spesolimab were consistent across different patient demographic and clinical characteristics.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Dermatology
Nina Magnolo, Thomas Jaenicke, Athanasios Tsianakas, Wolfgang Czech, Diamant Thaci, Andreas Pinter, Delphine Kerob, Samir Salah, Thomas A. Luger
Summary: This study aimed to investigate the efficacy of skin care products containing emollients and a syndet with the ability to improve skin barrier and microbiome in moderate to severe AD patients. The results showed that patients using this product had significant improvements in itchiness and quality of life after 10 weeks, while using 23% less product compared to the control group.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Henning Olbrich, Christian D. Sadik, Ralf J. Ludwig, Diamant Thaci, Katharina Boch
Summary: Dupilumab, approved for atopic dermatitis and prurigo nodularis, has shown effectiveness in treating various dermatologic diseases including bullous autoimmune diseases, eczema, prurigo, and alopecia areata.
Correction
Rheumatology
Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaci, Thilo Klopsch, Anja Plenske, Lisa K. Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Loeschmann
RHEUMATOLOGY AND THERAPY
(2023)
Article
Oncology
Kim A. Papp, Mark G. Lebwohl, Diamant Thaci, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C. Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Tina Pyo, Woori Ko
Summary: CT-P43 demonstrated equivalent efficacy to originator ustekinumab in adults with moderate to severe plaque psoriasis, with comparable pharmacokinetic, safety, and immunogenicity profiles.